Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 77

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 77
---
 is involuntarily terminated within 24 months after such change in control: (1) options and SARs shall become fully vested as of the termination date, and exercisable no later than 30 days following such termination date; (2) restricted shares and RSUs shall become fully vested as of such termination date, and shall be delivered no later than 30 days following such termination date; and (3) performance awards shall become vested pro rata (to the extent not already vested) at actual performance levels if such performance levels can be determined, or at target performance levels if the actual performance levels cannot be determined, as of the termination date, based on the portion of the performance period of the award that was completed as of the termination date, and shall be delivered no later than 30 days following such termination date.

In the event of a change in control in which the acquiring or surviving company does not assume or continue all outstanding awards under the 2025 Plan, all outstanding awards that are not assumed or continued shall be treated as follows in connection with such change in control to the extent permitted by Section 409A of the Code: (1) options and SARs shall become fully vested and exercisable as of immediately prior to the Change in Control; (2) restricted shares and RSUs shall become fully vested as of immediately prior to the change in control to the extent not already vested, and shall settle immediately following the change in control; and (3) performance awards shall become vested pro rata (to the extent not already vested) at actual performance levels if such performance levels can be determined, or at target performance levels if the actual performance levels cannot be determined, as of the change in control, based on the portion of the performance period of the award that was completed as of the change in control, and shall settle immediately following the change in control.

The transaction agreement may provide that outstanding awards, whether vested or unvested, shall be cancelled in exchange for cash and/or other consideration with a value equal to (1) for options or SARs, the excess (if any) of the fair market value of the shares underlying such award over the aggregate exercise price (or, where such fair market value does not exceed the exercise price, the transaction agreement may provide for the cancelation of such award for no consideration); and (2) for all other awards, the fair market value of the shares underlying such award on the date of such change in control.

A change in control includes:

any person acquiring beneficial ownership of more than